These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31322732)

  • 1. A response-adaptive randomization procedure for multi-armed clinical trials with normally distributed outcomes.
    Williamson SF; Villar SS
    Biometrics; 2020 Mar; 76(1):197-209. PubMed ID: 31322732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.
    Villar SS; Wason J; Bowden J
    Biometrics; 2015 Dec; 71(4):969-78. PubMed ID: 26098023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate-adjusted response-adaptive randomization for multi-arm clinical trials using a modified forward looking Gittins index rule.
    Villar SS; Rosenberger WF
    Biometrics; 2018 Mar; 74(1):49-57. PubMed ID: 28682442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive bandit-based designs using the Gittins index for multi-armed trials with normally distributed endpoints.
    Smith AL; Villar SS
    J Appl Stat; 2018; 45(6):1052-1076. PubMed ID: 29551849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
    Lin R; Thall PF; Yuan Y
    Biometrics; 2020 Mar; 76(1):304-315. PubMed ID: 31273750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familywise error control in multi-armed response-adaptive trials.
    Robertson DS; Wason JMS
    Biometrics; 2019 Sep; 75(3):885-894. PubMed ID: 30714095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2018 Jul; 20(5):85. PubMed ID: 30027336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
    Guo B; Yuan Y
    Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-adaptive randomization for clinical trials with continuous outcomes.
    Zhang L; Rosenberger WF
    Biometrics; 2006 Jun; 62(2):562-9. PubMed ID: 16918921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges.
    Villar SS; Bowden J; Wason J
    Stat Sci; 2015; 30(2):199-215. PubMed ID: 27158186
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
    Yan D; Wages NA; Dressler EV
    J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.
    Jiang Y; Zhao W; Durkalski-Mauldin V
    J Biopharm Stat; 2020; 30(1):69-88. PubMed ID: 31017843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive treatment allocation for comparative clinical studies with recurrent events data.
    Gao J; Su PF; Hu F; Cheung SH
    Biometrics; 2020 Mar; 76(1):183-196. PubMed ID: 31282997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal adaptive single-arm phase II trials under quantified uncertainty.
    Kunzmann K; Kieser M
    J Biopharm Stat; 2020; 30(1):89-103. PubMed ID: 31023135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.